Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S319000, C514S380000
Reexamination Certificate
active
06974821
ABSTRACT:
The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, closed head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of D-alanine (or a modified form thereof), provided that the composition is substantially free of D-cycloserine, and/or (ii) D-serine (or a modified form thereof), and/or (iii) 105 to 500 mg of D-cycloserine (or a modified form thereof), and/or (iv) N-methylglycine (or a modified form thereof).
REFERENCES:
patent: 3873722 (1975-03-01), Smythies
patent: 5015740 (1991-05-01), Kennis et al.
patent: 5051448 (1991-09-01), Shashoua
patent: 5061721 (1991-10-01), Cordi et al.
patent: 5112863 (1992-05-01), Hashimoto et al.
patent: 5187171 (1993-02-01), Cordi
patent: 5260324 (1993-11-01), Cordi et al.
patent: 5468763 (1995-11-01), Cordi et al.
patent: 5482967 (1996-01-01), Natsugari et al.
patent: 5633281 (1997-05-01), Teall et al.
patent: 5837730 (1998-11-01), Javitt
patent: 5854286 (1998-12-01), Javitt et al.
patent: 6162827 (2000-12-01), Javitt
patent: 6228875 (2001-05-01), Tsai et al.
patent: 6355681 (2002-03-01), Javitt
patent: 6361957 (2002-03-01), Javitt
patent: 2002/0161048 (2002-10-01), Javitt
patent: 41 17 629 (1992-12-01), None
patent: 0 387 867 (1990-09-01), None
patent: 0 432 039 (1991-06-01), None
patent: 0 652 012 (1995-05-01), None
patent: 0 696 586 (1996-02-01), None
patent: P9200192 (2003-01-01), None
patent: 55 020747 (1980-02-01), None
patent: 08026986 (1996-01-01), None
patent: 2096044 (1997-11-01), None
patent: WO 89/05144 (1989-06-01), None
patent: WO 97/20552 (1997-06-01), None
patent: WO 97/20553 (1997-06-01), None
Barnes et al., “A Rating Scale for Drug-Induced Akathisia”British Journal of Psychiatry154:672-676, 1989.
Bart et al., “Efficacy and Tolerance of D-Cycloserine in Drug-Free Schizophrenic Patients”Biological Psychiatry40:1298-1300, 1996.
Baxter et al., “D-Cycloserine, a Novel Cognitive Enhancer, Improves Spatial Memory in Aged Rats”Neurobiology of Aging15:207-213, 1994.
Baxter et al., “Modulation of the NMDA Receptor Complex by D-Cycloserine”CNS Drug Reviews1:74-90, 1995.
Cascella et al., “d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study”Journal of Neural Transmission95:10-111, 1994.
Chessell et al., “D-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimér brain”Brain Research565:345-348, 1991.
Contreras, “D-Serine Antagonized Phencyclidine- and MK-801-Induced Stereotyped Behavior and Ataxia”Neuropharmacology29:291-293, 1990.
Crane, “Cycloserine as an Antidepressant Agent”,The American Journal of Psychiatry115:1025-1026, 1959.
Cutler et al., “The Tolerability and Efficacy of Cycloserine in Alzheimer's Disease”Am. Coll. Neuropsychopharmacol. Annual Meeting, Puerto Rico, 1994.
D'Souza et al., “Glycine Site Agonists of the NMDA Receptor: A Review”CNS Drug Reviews1:227-260, 1995.
Falk et al., “A Case Series of D-Cycloserine Added to Donepezil in the Treatment of Alzheimer's Disease”J. Neuropsychiatry Clin. Neurosci. 14:466-467, 2002.
Fishkin et al., “D-Cycloserine Attenuates Scopolamine-Induced Learning and Memory Deficits in Rats”Behavioral and Neural Biology59:150-157, 1993.
Francis et al., “A Glycine Site as Therapeutic Target” Institute of Neurology, Miriam Marks Department of Neurochemistry; London, WCIN, IPJ, United Kingdom, pp. 184-188, (no date available).
Goff et al., “D-Cycloserine Added to Clozapine for Patients With Schizophrenia”Am. J. Psychiatry153:1628-1630, 1996.
Goff et al., “Dose-Finding Trial of D-Cycloserine Added to Neuroleptics for Negative Symptoms in Schizophrenia”Am. J. Psychiatry152:1213-1215, 1995.
Hashimoto et al., “D-Alanine inhibits methamphetamine-induced hyperactivity in rats”European Journal of Pharmacology202:105-107, 1991.
Javitt et al., “Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schzophrenia and substance abuse”Psychopharmacology129:96-98, 1997.
Javitt et al., “Reversal of Phencyclidine-Induced Hyperactivity by Glycine and the Glycine Update Inhibitor Glycyldodecylamide”Neuropsychopharmacology17:202-204, 1997.
Kay et al., “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia”Schizophrenia Bulletin National Institute of Mental Health13:261-276, 1987.
Kirkpatrick et al., “The Schedule for the Deficit Syndrome: An Instrument for Research in Schizophrenia”Psychiatry Research30:119-123, 1989.
Kumashiro et al., “Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases”Brain Res. 681:117-125, 1997.
Leiderman et al., “Preliminary Investigation of High-Dose Oral Glycine in Serum Levels and Negative Symptoms in Schizophrenia: An Open-Label Trial”Biological Psychiatry, 39:213-215, 1996.
Lindenmayer et al., “Five-Factor Model of Schizophrenia Initial Validation”The Journal of Nervous and Mental Disease182:631-638, 1994.
Lingjaerde et al., “The UKU side effects rating scale”Scandinavian Society of Psychopharmacology Committee of Clinical Investigations(UKU); pp. 81-94, 1986.
Malhotra et al., “NMDA receptor function and human cognition the effects of ketamine in healthy volunteers”Neuropsychopharmacology14:301-307, 1996.
Matsuoka et al., “D-Cycloserine, a Partial Agonist at the Glycine Site Coupled to N-Methyl-D-aspartate Receptors, Improves Visual Recognition Memory In Rhesus Monkeys”The Journal of Pharmacology and Experimental Therapeutics278:891-897, 1996.
McKhann et al., “Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department . . . ”Neurology34:939-944, 1984.
Monahan et al., “Characterization of a [3H]Glycine Recognition Site as a Modulatory Site of the N-Methyl-D-Aspartate Receptor Complex”Journal of Neurochemistry53:370-375, 1989.
Morrison and Body, “Carboxylic Acids,” Chapter 23, pp. 822-823, inOrganic Chemistry, Fifth ed. Boston: Allyn and Bacon, Inc., (no date available).
Nilsson et al., “Glycine and D-serine decrease MK-801-induced hyperactivity in mice”J. Neural. Transm104:1195-1205, 1997.
Nishikawa et al., “PCP-induced abnormal behavior and c-fos gene expression in the brain as indices for neuroleptic-resistant symptoms of schizophrenia”Folia Pharmacological Japonica, Patent Abstract XP-002117995, 1996.
Papp et al., “Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression”European Journal of Pharmacology316:145-151, 1996.
Patent Abstract; XP-002117996; JP55020747 A; “Antidepressant Drug Low Side Effect Contain Serine Salt Effect Component” 1980.
Patent Abstract; XP-002117997; JP08026986; “Anti-phencyclidine drugs contain D-serine esters of formula (I) or their salts as active agents” 1996.
Prous et al., “D-Cycloserine”Drugs of the Future19: 988-991, 1994.
Ramakers et al., “The Impaired Long-Term Potentiation in the CA1 Field of the Hippocampus of Cognitive Deficient Microencephalic Rats is Restored by D-Serine”Neuroscience54:49-60, 1993.
Ramakrishna et al., “Betaine reverses toxic effects of aluminium: Implications in Alzheimer's disease (AD) and AD-like pathology”Current Science75:1153-1156, 1998.
Randolph et al., “D-Cycloserine Treatment of Alzheimer Disease”Alzheimer Disease and Associate Disorders8:198
Coyle Joseph
Tsai Guochuan
Fish & Richardson P.C.
Henley III Raymond J.
The General Hospital Corporation
LandOfFree
Methods for treating neuropsychiatric disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating neuropsychiatric disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating neuropsychiatric disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501273